Project Grant R21AI187955
Award Date
7/10/25
Completion Date
6/30/27
Dollars Obligated
$461K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
This Project Grant award of $3,262,539.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research by Yale University to elucidate the molecular mechanisms underlying the assembly of the mycobacterial cell envelope, a critical barrier to antibiotics and important target for drug development. The key research aims include investigating the cytoplasmic synthesis and transport of mycolic acids, defining the physiological...
This Project Grant award of $176,152, provided by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify new drug targets against drug-tolerant strains of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The research aims to study the role of lipid metabolism and host-pathogen interactions in conferring drug tolerance to MTB strains with deficient glycerol...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $294,824 to the University of Massachusetts Medical School (UMass Medical) to investigate strategies for enhancing the efficacy of antibiotics against Mycobacterium tuberculosis (MTB) infections. The key objectives are to understand the mechanistic link between glutamine starvation, immune pressure vulnerability, and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,944,529.00 to Weill Medical College of Cornell University to conduct research on understanding resistance and tolerance to the nitroimidazole drugs pretomanid (PA) and delamanid (DLM) in Mycobacterium tuberculosis (MTB). The key objectives are to apply innovative genome-wide screens to identify MTB genes...
This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $711,993.00 to Boston Medical Center Corporation to conduct research on the impact of Mycobacterium tuberculosis (MTB) disease on HIV-1 immunity, evolution, and persistence. The research aims to examine how MTB disease affects the development of broadly potent HIV-1 neutralizing antibodies, the emergence of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $404,108 to the University of California, Davis (UC Davis) to identify genetic and signaling pathways that enable Mycobacterium tuberculosis (MTB) persister cells to survive antibiotic treatment. The award aims to apply genetic and proteomic approaches to uncover the core mechanisms driving MTB...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, is funding research to investigate how Mycobacterium tuberculosis (MTB) infection triggers host cell death mechanisms. The $819,998 award to The Regents of the University of California, San Francisco (UCSF) aims to elucidate the regulatory roles of autophagy factors TAX1BP1 and optineurin in modulating MTB pathogenesis and host cell death...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $415,978 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Central Florida. The grant aims to identify novel boron-based inhibitors of mycobacterial class II aminoacyl-tRNA synthetases, which are essential enzymes for protein synthesis in Mycobacterium tuberculosis (MTB). The research will use a high-throughput screening assay to test a library of boron-containing...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA program 93.855 "Allergy and Infectious Diseases Research," is providing $813,373 to Rutgers, The State University of New Jersey to conduct research on developing new classes of pyrazinoic acid prodrugs against pyrazinamide-resistant Mycobacterium tuberculosis. The goal is to characterize the diverse set of Mycobacterium tuberculosis amidases and the compound structures...